# MARAVAI LIFESCIENCES HOLDINGS, INC.

Summary updated: 2026-10-02T12:41:15.538048Z
Canonical: https://finbar.com/research/companies/maravai-lifesciences-holdings-inc

## Overview

Maravai LifeSciences Holdings, Inc. is a life-sciences tools and services company that supplies products and services used in biopharmaceutical research, development, and manufacturing. Its customers use these offerings in areas including gene therapy, vaccines, oligonucleotide therapeutics, molecular diagnostics, and biologics manufacturing. [1](https://app.finbar.com/go?id=P197763666)

The company operates through TriLink, which develops and manufactures nucleic-acid products and related technologies, and Cygnus, which provides biologics safety-testing and analytical products and services. Maravai says it serves customers in approximately 60 countries through direct sales and distributors. [2](https://app.finbar.com/go?id=P197763312)[3](https://investors.maravai.com/sec-filings/annual-reports/content/0001193125-26-177478/0001193125-26-177478.pdf) Its stated mission is to empower customers to turn ideas into innovations, from discovery to delivery. [4](https://www.maravai.com/who-we-are/)

Maravai reported FY2025 revenue of $185.7 million and 435 full-time employees globally as of December 31, 2025. [5](https://app.finbar.com/go?id=T19830059)[6](https://investors.maravai.com/company-information/faq) Founded in 2014, it later became publicly traded on Nasdaq in 2020. [7](https://www.maravai.com/impact/)[8](https://investors.maravai.com/news-events/press-releases/detail/50/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering)
[1](https://app.finbar.com/go?id=P197763666)[2](https://app.finbar.com/go?id=P197763312)[3](https://investors.maravai.com/sec-filings/annual-reports/content/0001193125-26-177478/0001193125-26-177478.pdf)[4](https://www.maravai.com/who-we-are/)[5](https://app.finbar.com/go?id=T19830059)[6](https://investors.maravai.com/company-information/faq)[7](https://www.maravai.com/impact/)[8](https://investors.maravai.com/news-events/press-releases/detail/50/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering)[3](https://investors.maravai.com/sec-filings/annual-reports/content/0001193125-26-177478/0001193125-26-177478.pdf)[4](https://www.maravai.com/who-we-are/)[6](https://investors.maravai.com/company-information/faq)[7](https://www.maravai.com/impact/)[8](https://investors.maravai.com/news-events/press-releases/detail/50/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering)

## Products & services

TriLink supplies nucleic-acid products and related development and manufacturing services for gene therapy, vaccines, oligonucleotide therapies and molecular diagnostics. Its products include mRNA, long- and short-chain oligonucleotides, synthesis inputs, nucleoside triphosphates (NTPs) and specialty enzymes. CleanCap® is a patented mRNA-capping technology offered as a research-use-only or GMP-grade reagent, either standalone or with synthesis inputs; it is designed to improve co-transcriptional capping efficiency and reduce uncapped mRNA. ModTail™ modifies mRNA poly(A) tails and is described as increasing protein expression and its duration. TriLink also provides custom and discovery-stage mRNA synthesis, process development and scale-up, and GMP manufacturing from clinical through commercial production, alongside analytical characterization and regulatory-submission support. Its enzyme capabilities include custom scalable enzymes and a proprietary T7 enzyme used to reduce double-stranded RNA during in-vitro transcription. [9](https://app.finbar.com/go?id=P197762652)[10](https://app.finbar.com/go?id=P197762656)[11](https://app.finbar.com/go?id=P197762657)[12](https://app.finbar.com/go?id=P197762658)[13](https://app.finbar.com/go?id=P197762665)[14](https://app.finbar.com/go?id=P197762667)[15](https://app.finbar.com/go?id=P197762668)

Cygnus offers biologics safety and impurity-testing products and analytical services used during development, scale-up and commercialization. Products include host-cell-protein ELISA kits, other process-impurity and containment ELISA kits, viral-clearance prediction kits and ancillary reagents. Its MockV® MVM and RVLP kits use non-infectious mock virus particles that mimic live-virus physicochemical properties for in-house viral-clearance assessments. Services include custom antibody and assay development, antibody-affinity extraction and mass spectrometry. [16](https://app.finbar.com/go?id=P197762670)[17](https://app.finbar.com/go?id=P197762672)[18](https://app.finbar.com/go?id=P197762674)[19](https://app.finbar.com/go?id=P197764106)

The 2025 filing reports segment revenue of $119.787 million for TriLink and $65.956 million for Cygnus, approximately 64.5% and 35.5% of total revenue, respectively; these are segment shares, not percentages attributable to individual products. [20](https://app.finbar.com/go?id=T19830052)
[9](https://app.finbar.com/go?id=P197762652)[10](https://app.finbar.com/go?id=P197762656)[11](https://app.finbar.com/go?id=P197762657)[12](https://app.finbar.com/go?id=P197762658)[13](https://app.finbar.com/go?id=P197762665)[14](https://app.finbar.com/go?id=P197762667)[15](https://app.finbar.com/go?id=P197762668)[16](https://app.finbar.com/go?id=P197762670)[17](https://app.finbar.com/go?id=P197762672)[18](https://app.finbar.com/go?id=P197762674)[19](https://app.finbar.com/go?id=P197764106)[20](https://app.finbar.com/go?id=T19830052)[20](https://app.finbar.com/go?id=T19830052)[20](https://app.finbar.com/go?id=T19830052)

## Geographic presence

Maravai’s disclosed facilities are located in the United States: San Diego, California (237,000 sq. ft.); Sterling, Virginia (21,000 sq. ft.); Leland, North Carolina (46,000 sq. ft.); Southport, North Carolina (20,000 sq. ft.); and Jupiter, Florida (22,000 sq. ft.). [21](https://app.finbar.com/go?id=T19830044) The company’s corporate headquarters and certain research and development operations are in San Diego, which is also identified as TriLink’s principal hub. [22](https://app.finbar.com/go?id=P197763273) Its principal executive office is at 10770 Wateridge Circle, Suite 200, San Diego, California. [23](https://app.finbar.com/go?id=P197762606)

Maravai sells mainly through a direct sales force and uses distributors in some international markets where it has no direct commercial presence; the cited disclosure does not identify those markets. [24](https://app.finbar.com/go?id=P197763682) A country- or region-level revenue breakdown was not identified in the available reporting. The company has also described a U.S. domestic manufacturing expansion at its Flanders campus in San Diego. [25](https://app.finbar.com/go?id=P197763933)
[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[21](https://app.finbar.com/go?id=T19830044)[22](https://app.finbar.com/go?id=P197763273)[23](https://app.finbar.com/go?id=P197762606)[24](https://app.finbar.com/go?id=P197763682)[25](https://app.finbar.com/go?id=P197763933)

## Business segments

Maravai reports two operating segments: **TriLink** and **Cygnus**. TriLink develops and supplies modified nucleic-acid products and related services for research, therapeutic, and vaccine applications. Its offerings include mRNA, oligonucleotides and building blocks, custom enzymes, and contract development and manufacturing services; applications include gene therapy, vaccines, oligonucleotide therapeutics, and molecular diagnostics. [26](https://app.finbar.com/go?id=P196851643)[27](https://app.finbar.com/go?id=P196851898)

Cygnus focuses on biologic-safety testing and analytical products and services used in biologic manufacturing and process development. Its products include assays for host-cell proteins, bioprocess impurities, and viral-clearance prediction, alongside custom assay and antibody development and other analytical services. [26](https://app.finbar.com/go?id=P196851643)[28](https://app.finbar.com/go?id=P196851836) By revenue, TriLink accounted for 67.4% and Cygnus 32.6% in the three months ended June 30, 2026; for full-year 2025, their respective shares were 64.5% and 35.5%. [29](https://app.finbar.com/go?id=P196851945)[30](https://app.finbar.com/go?id=P197763420)
[26](https://app.finbar.com/go?id=P196851643)[27](https://app.finbar.com/go?id=P196851898)[28](https://app.finbar.com/go?id=P196851836)[29](https://app.finbar.com/go?id=P196851945)[30](https://app.finbar.com/go?id=P197763420)

## Company history

Maravai LifeSciences was formed in March 2014 as a partnership between Carl Hull, Eric Tardif and GTCR; Hull later served as the company’s CEO and co-founder. [31](https://investors.maravai.com/news-events/press-releases/detail/5/maravai-lifesciences-announces-ceo-leadership-transition) In October 2016, it acquired TriLink BioTechnologies and Cygnus Technologies, establishing two of its early operating platforms. [32](https://www.trilinkbiotech.com/press-releases/maravai-lifesciences-acquires-trilink-biotechnologies) [33](https://www.cygnustechnologies.com/press-releases/maravai-lifesciences-acquires-cygnus-technologies) It expanded its nucleic-acid reagent portfolio with the acquisition of Glen Research in January 2018. [34](https://www.glenresearch.com/press-releases/maravai-lifesciences-acquires-glen-research-corporation)

Maravai went public in November 2020, with its Class A shares beginning to trade on Nasdaq under the ticker MRVI. [8](https://investors.maravai.com/news-events/press-releases/detail/50/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering) In 2021, it sold Vector Laboratories, its Protein Detection business. [35](https://app.finbar.com/go?id=P197764211) In 2022, the company agreed to acquire Alphazyme, completing the acquisition in 2023. [36](https://investors.maravai.com/news-events/press-releases/detail/59/maravai-lifesciences-reports-fourth-quarter-and-full-year-2022-financial-results) That year, co-founder Carl Hull transitioned to Executive Chairman and Trey Martin became CEO. [31](https://investors.maravai.com/news-events/press-releases/detail/5/maravai-lifesciences-announces-ceo-leadership-transition) In 2025, Bernd Brust was appointed CEO and Rajesh Asarpota CFO. [37](https://app.finbar.com/go?id=P197763332)
[35](https://app.finbar.com/go?id=P197764211)[37](https://app.finbar.com/go?id=P197763332)[31](https://investors.maravai.com/news-events/press-releases/detail/5/maravai-lifesciences-announces-ceo-leadership-transition)[32](https://www.trilinkbiotech.com/press-releases/maravai-lifesciences-acquires-trilink-biotechnologies)[33](https://www.cygnustechnologies.com/press-releases/maravai-lifesciences-acquires-cygnus-technologies)[34](https://www.glenresearch.com/press-releases/maravai-lifesciences-acquires-glen-research-corporation)[8](https://investors.maravai.com/news-events/press-releases/detail/50/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering)[36](https://investors.maravai.com/news-events/press-releases/detail/59/maravai-lifesciences-reports-fourth-quarter-and-full-year-2022-financial-results)

## Sources

1. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763666)
2. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763312)
3. [investors.maravai.com](https://investors.maravai.com/sec-filings/annual-reports/content/0001193125-26-177478/0001193125-26-177478.pdf)
4. [www.maravai.com](https://www.maravai.com/who-we-are/)
5. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T19830059)
6. [investors.maravai.com](https://investors.maravai.com/company-information/faq)
7. [www.maravai.com](https://www.maravai.com/impact/)
8. [investors.maravai.com](https://investors.maravai.com/news-events/press-releases/detail/50/maravai-lifesciences-announces-pricing-of-an-upsized-initial-public-offering)
9. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762652)
10. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762656)
11. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762657)
12. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762658)
13. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762665)
14. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762667)
15. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762668)
16. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762670)
17. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762672)
18. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762674)
19. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197764106)
20. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T19830052)
21. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=T19830044)
22. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763273)
23. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197762606)
24. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763682)
25. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763933)
26. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P196851643)
27. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P196851898)
28. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P196851836)
29. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2026 Q 2)](https://app.finbar.com/go?id=P196851945)
30. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763420)
31. [investors.maravai.com](https://investors.maravai.com/news-events/press-releases/detail/5/maravai-lifesciences-announces-ceo-leadership-transition)
32. [www.trilinkbiotech.com](https://www.trilinkbiotech.com/press-releases/maravai-lifesciences-acquires-trilink-biotechnologies)
33. [www.cygnustechnologies.com](https://www.cygnustechnologies.com/press-releases/maravai-lifesciences-acquires-cygnus-technologies)
34. [www.glenresearch.com](https://www.glenresearch.com/press-releases/maravai-lifesciences-acquires-glen-research-corporation)
35. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197764211)
36. [investors.maravai.com](https://investors.maravai.com/news-events/press-releases/detail/59/maravai-lifesciences-reports-fourth-quarter-and-full-year-2022-financial-results)
37. [MARAVAI LIFESCIENCES HOLDINGS, INC. — Full financial report (2025 Y)](https://app.finbar.com/go?id=P197763332)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.